Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
Review Special Issue Series—Measuring Neutralizing Antibody Responses Against SARS-CoV-2 and...
share announcement

Review Special Issue Series—Measuring Neutralizing Antibody Responses Against SARS-CoV-2 and Emerging Infectious Diseases

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Therapeutic Vaccines and Antibody Therapeutics".

Deadline for manuscript submissions: 31 May 2025 | Viewed by 5521

Special Issue Editor

Dr. Ruth Harvey

E-Mail
Guest Editor
The Francis Crick Institute, London, UK
Interests: Influenza; SARS-CoV-2; serology; vaccines; clinically relevant; animal-human interface

Special Issue Information

Dear Colleagues 

As the guest editor, I am pleased to announce the Special Issue “Measuring Neutralizing Antibody Responses against SARS-CoV-2 and Emerging Infectious Diseases”, in which we aim to encourage more submissions of review papers. Please note the following instructions:

  1. The word count should be more than 3000 words in the main text;
  2. Manuscripts must cite the newest published research;
  3. Manuscripts must comprehensively summarize the current hot topics. 

Vaccines will provide full support for long reviews (5000 or more words in the main text) of high quality. For more detailed information, please do not hesitate to contact the Vaccines Office: vaccines@mdpi.com.

Dr. Ruth Harvey
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • SARS-CoV-2
  • neutralizing
  • antibody
  • infectious
  • diseases

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 856 KiB  
Article
Fc-Modified Antibody in Hospitalized Severe COVID-19 Patients
by Felipe Dal-Pizzol, Suzana Margareth Lobo, Christopher Lucasti, Adam Abdul Hakeem Baidoo, Huo Su, Zhanghua Lan and Liangzhi Xie
Vaccines 2025, 13(4), 372; https://doi.org/10.3390/vaccines13040372 - 31 Mar 2025
Viewed by 314
Abstract
Background: Hospitalized patients with severe COVID-19 are at high risk of clinical deterioration. Methods: A global, randomized, double-blinded, and placebo-controlled phase II trial that investigated the clinical efficacy of SCTA01, an Fc-modified monoclonal antibody, in patients hospitalized with severe COVID-19 during the Delta [...] Read more.
Background: Hospitalized patients with severe COVID-19 are at high risk of clinical deterioration. Methods: A global, randomized, double-blinded, and placebo-controlled phase II trial that investigated the clinical efficacy of SCTA01, an Fc-modified monoclonal antibody, in patients hospitalized with severe COVID-19 during the Delta variant wave was performed. The primary outcome was time to clinical improvement up to Day 29. Secondary outcomes measured the all-cause mortality rate up to Day 29, time to SARS-CoV-2 RNA negativity up to Day 29, and the number of antibody-dependent enhancements. Results: From 27 March 2021, to 11 February 2022, 102 hospitalized adults with severe COVID-19 received a single intravenous infusion of SCTA01 15 mg/kg or 50 mg/kg or placebo in a 1:1:1 ratio. The median time to clinical improvement in the SCTA01 group was numerically shorter than that in the placebo group; however, the between group difference was statistically non-significant (SCTA01 15 mg/kg vs. placebo, HR 0.99, 95% CI 0.55–1.77, p = 0.742; SCTA01 50 mg/kg vs. placebo, HR 1.07, 95% CI 0.61–1.88, p = 0.095). The median time to achieve a negative SARS-CoV-2 status was shorter in the SCTA01 15 mg/kg group (14.0 days vs. 27.0 days) but not in the SCTA01 50 mg/kg group (28.0 days vs. 27.0 days) compared to the placebo group. Adverse events were comparable across all groups, and no treatment-related serious adverse event or antibody-dependent enhancement was reported. Conclusions: The Fc-modified antibody was safe but lacked significant clinical efficacy in vivo, likely due to the SARS-CoV-2 viral mutation. Full article
(This article belongs to the Special Issue Review Special Issue Series—Measuring Neutralizing Antibody Responses Against SARS-CoV-2 and Emerging Infectious Diseases)
►▼ Show Figures

Figure 1

13 pages, 1289 KiB  
Article
Immunogenicity of Tetravalent Protein Vaccine SCTV01E-2 against SARS-CoV-2 EG.5 Subvaraint: A Phase 2 Trial
by Jihai Tang, Qinghua Xu, Chaoyin Zhu, Kun Xuan, Tao Li, Qingru Li, Xingya Pang, Zhenqiu Zha, Jinwei Li, Liyang Qiao, Haiyang Xu, Gang Wu, Yan Tian, Jun Han, Cuige Gao, Jiang Yi, Gui Qian, Xuxin Tian and Liangzhi Xie
Vaccines 2024, 12(2), 175; https://doi.org/10.3390/vaccines12020175 - 8 Feb 2024
Cited by 5 | Viewed by 1899
Abstract
The Omicron EG.5 lineage of SARS-CoV-2 is currently on a trajectory to become the dominant strain. This phase 2 study aims to evaluate the immunogenicity of SCTV01E-2, a tetravalent protein vaccine, with a specific emphasis on its immunogenicity against Omicron EG.5, comparing it [...] Read more.
The Omicron EG.5 lineage of SARS-CoV-2 is currently on a trajectory to become the dominant strain. This phase 2 study aims to evaluate the immunogenicity of SCTV01E-2, a tetravalent protein vaccine, with a specific emphasis on its immunogenicity against Omicron EG.5, comparing it with its progenitor vaccine, SCTV01E (NCT05933512). As of 12 September 2023, 429 participants aged ≥18 years were randomized into the groups SCTV01E (N = 215) and SCTV01E-2 (N = 214). Both vaccines showed increases in neutralizing antibody (nAb) against Omicron EG.5, with a 5.7-fold increase and a 9.0-fold increase in the SCTV01E and SCTV01E-2 groups 14 days post-vaccination, respectively. The predetermined statistical endpoints were achieved, showing that the geometric mean titer (GMT) of nAb and the seroresponse rate (SRR) against Omicron EG.5 were significantly higher in the SCTV01E-2 group than in the SCTV01E group. Additionally, SCTV01E and SCTV01E-2 induced a 5.5-fold and a 5.9-fold increase in nAb against XBB.1, respectively. Reactogenicity was generally mild and transient. No vaccine-related serious adverse events (SAEs), adverse events of special interest (AESIs), or deaths were reported. In summary, SCTV01E-2 elicited robust neutralizing responses against Omicron EG.5 and XBB.1 without raising safety concerns, highlighting its potential as a versatile COVID-19 vaccine against SARS-CoV-2 variants. Full article
(This article belongs to the Special Issue Review Special Issue Series—Measuring Neutralizing Antibody Responses Against SARS-CoV-2 and Emerging Infectious Diseases)
►▼ Show Figures

Figure 1

Review

Jump to: Research

20 pages, 587 KiB  
Review
A Review of Protein-Based COVID-19 Vaccines: From Monovalent to Multivalent Formulations
by Gui Qian, Cuige Gao, Miaomiao Zhang, Yuanxin Chen and Liangzhi Xie
Vaccines 2024, 12(6), 579; https://doi.org/10.3390/vaccines12060579 - 25 May 2024
Cited by 4 | Viewed by 2604
Abstract
The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulting in the COVID-19 pandemic, has profoundly impacted global healthcare systems and the trajectory of economic advancement. As nations grapple with the far-reaching consequences of this unprecedented health crisis, the administration of [...] Read more.
The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulting in the COVID-19 pandemic, has profoundly impacted global healthcare systems and the trajectory of economic advancement. As nations grapple with the far-reaching consequences of this unprecedented health crisis, the administration of COVID-19 vaccines has proven to be a pivotal strategy in managing this crisis. Protein-based vaccines have garnered significant attention owing to their commendable safety profile and precise immune targeting advantages. Nonetheless, the unpredictable mutations and widespread transmission of SARS-CoV-2 have posed challenges for vaccine developers and governments worldwide. Monovalent and multivalent vaccines represent two strategies in COVID-19 vaccine development, with ongoing controversy surrounding their efficacy. This review concentrates on the development of protein-based COVID-19 vaccines, specifically addressing the transition from monovalent to multivalent formulations, and synthesizes data on vaccine manufacturers, antigen composition, pivotal clinical study findings, and other features that shape their distinct profiles and overall effectiveness. Our hypothesis is that multivalent vaccine strategies for COVID-19 could offer enhanced capability with broad-spectrum protection. Full article
(This article belongs to the Special Issue Review Special Issue Series—Measuring Neutralizing Antibody Responses Against SARS-CoV-2 and Emerging Infectious Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop